Abbott announced completion of its $23 billion acquisition of Exact Sciences after regulatory clearances, folding Cologuard, Oncotype DX and other cancer‑screening assays into Abbott’s diagnostics portfolio. Abbott said the deal will add roughly $3 billion in incremental sales in 2026 and accelerate its diagnostic growth strategy. Abbott framed the purchase as a strategic move to enter multi‑cancer early detection and expand its presence across oncology diagnostics. For readers: Cologuard is a stool‑based DNA methylation test for colorectal cancer screening, while Oncotype DX provides genomic risk stratification for breast cancer treatment decisions. Management cautioned on near‑term EPS dilution tied to financing, but emphasized long‑term revenue synergies as Abbott integrates Exact’s assay development and commercial channels into its global diagnostics footprint.